

**FDA-APPROVED NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENTS**

Generic <b>Angiogenesis inhibitor</b>	Brand	Strength	Form	Usual Dose
bevacizumab	<b>Avastin</b>	100mg, 400mg	soln for IV infusion after dilution	15mg/kg once every 3wks with carboplatin/ paclitaxel
<b>Antimetabolites</b>				
gemcitabine	<b>Gemzar</b>	200mg, 1g	pwd for IV infusion after reconstitution	1000mg/m <sup>2</sup> on Days 1, 8, and 15 of each 28 day cycle; or 1250mg/m <sup>2</sup> on Days 1 and 8 of each 21 day cycle
methotrexate	<b>Methotrexate injection</b>	25mg/mL 1g	soln for IV, IM, intra-arterial, or intrathecal administration after dilution pwd for IV, IM, intra-arterial, or intrathecal administration after dilution	See drug entry and manufacturer's literature
	<b>Trexall</b>	5mg, 7.5mg, 10mg, 15mg	scored tabs	
pemetrexed	<b>Alimta</b>	100mg, 500mg	pwd for IV inj after reconstitution and dilution	500mg/m <sup>2</sup> on Day 1 of each 21-day cycle
<b>Antimicrotubule agents</b>				
docetaxel	<b>Taxotere</b>	40mg/mL	soln for IV infusion after dilution	75mg/m <sup>2</sup> once every 3wks
paclitaxel	<b>Taxol</b>	6mg/mL	soln for IV infusion after dilution	135mg/m <sup>2</sup> IV plus cisplatin every 3wks
paclitaxel [bound to albumin (human)]	<b>Abraxane</b>	100mg/vial	pwd for IV infusion after reconstitution	100mg/m <sup>2</sup> on Days 1, 8, and 15 of each 21-day cycle
vinorelbine	<b>Navelbine</b>	10mg/mL	soln for IV inj after dilution	Monotherapy: 30mg/m <sup>2</sup> once weekly Combination therapy: 25mg/m <sup>2</sup> once weekly given every 4wks; or 30mg/m <sup>2</sup> once weekly given on Days 1 and 29, then every 6wks
<b>Photosensitizing agent</b>				
porfimer	<b>Photofrin</b>	75mg	pwd for IV inj after reconstitution	2mg/kg then illumination with laser light 40-50hrs following injection
<b>Tyrosine Kinase Inhibitors</b>				
afatinib	<b>Gilotrif</b>	20mg, 30mg, 40mg	tabs	40mg once daily on empty stomach
crizotinib	<b>Xalkori</b>	200mg, 250mg	caps	250mg twice daily
erlotinib	<b>Tarceva</b>	25mg, 100mg, 150mg	tabs	150mg once daily

**NOTES**

Not an inclusive list of medications, official indications, and/or dosing details. Please see drug monograph at [www.eMPR.com](http://www.eMPR.com) and/or contact company for full drug labeling.  
(Rev. 6/2014)